SequelSEC

Kalaris Therapeutics, Inc. KLRS

Biological Products, (No Diagnostic Substances) · CIK 0001754068 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2019-12-31
Operating income
-$9.50M
Fiscal year ended 2019-12-31
Free cash flow
-$8.99M
Fiscal year ended 2019-12-31

Kalaris Therapeutics, Inc. (KLRS) reported revenue of $0 and net income of -$8.74M for the fiscal year ended 2019-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Kalaris Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Kalaris Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-312019-09-302019-06-30
Revenue$0$0Unavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$9.50M-$8.48M-$5.94M
Net income-$8.74M-$7.27M-$5.30M
Research & development$6.69M$5.66M$2.76M
Weighted-average diluted sharesUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailable
Diluted EPSUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$2.82M$2.82M$3.19M
Selling & marketingUnavailableUnavailableUnavailable

Balance

Kalaris Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-312019-09-302019-06-30
Cash & equivalents$61.08MUnavailableUnavailable
Total assets$139.42MUnavailableUnavailable
Current assets$127.31MUnavailableUnavailable
Total liabilities$17.80MUnavailableUnavailable
Current liabilities$9.11MUnavailableUnavailable
Total equity incl. NCI-$51.50M-$43.35M-$36.65M
Temporary (mezzanine) equity$173.13MUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$630.00KUnavailableUnavailable

Cash flow

Kalaris Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-312019-09-302019-06-30
Operating cash flow-$8.87M-$6.40MUnavailable
Capital expenditures$121.00K-$7.00KUnavailable
Investing cash flow$34.88M$46.00KUnavailable
Financing cash flow$0$0Unavailable
Net change in cash$26.01M-$6.36MUnavailable
Stock-based compensation$622.00K$596.00KUnavailable
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

Kalaris Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-312019-09-302019-06-30
Free cash flow-$8.99MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio13.98xUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open KLRS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.